BPC 157 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-04. Numbers and descriptions here follow the published literature rather than marketing material.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
=== Aviptadil === In the wake of the COVID-19 pandemic, scientists at Relief conducted initial studies into the efficacy of RLF-100 in treating severe COVID-19 patients. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19. In September 2020, Relief partnered with US-Israeli firm NRX Pharmaceuticals (formerly NeuroRx Inc) for the co-development of the drug and the co-ordination of US trials. In April 2021, a reformulated version of aviptadil, known as Zyesami, was included in a National Institutes of Health (NIH) sponsored Phase 3 trial with the aim of testing aviptadil against remdesivir. In May 2021, NRX submitted a request for an Emergency Use Authorization (EUA) to the US FDA for aviptadil's use in patients in intensive care. On 7 October 2021 Relief Therapeutics filed a lawsuit against NRX Pharmaceuticals and its CEO Dr. Jonathan Javitt in the Supreme Court of the State of New York, citing multiple alleged breaches of the collaboration agreement signed by the two companies for the co-development of aviptadil. On 4 November 2021 the FDA declined EUA for the drug, but committed to working with NRX to further develop it. On 29 November 2021, NRX announced that data analysis from the NIH-sponsored Phase 3 trial showed a fourfold increase in survival at 60 days for patients administered with Zyesami (Aviptadil) vs those who received placebo.
== Labeling methods == Proteins can be biotinylated chemically or enzymatically. Chemical biotinylation utilises various conjugation chemistries to yield nonspecific biotinylation of amines, carboxylates, sulfhydryls and carbohydrates (e.g., NHS-coupling gives biotinylation of any primary amines in the protein). Enzymatic biotinylation results in biotinylation of a specific lysine within a certain sequence by a bacterial biotin ligase. Most chemical biotinylation reagents consist of a reactive group attached via a linker to the valeric acid side chain of biotin. As the biotin binding pocket in avidin / streptavidin is buried beneath the protein surface, biotinylation reagents possessing a longer linker are desirable, as they enable the biotin molecule, once it has been attached to its target, to be more accessible to binding avidin/streptavidin/Neutravidin protein. This linker can also mediate the solubility of biotinylation reagents; linkers that incorporate poly(ethylene) glycol (PEG) can make water-insoluble reagents soluble or increase the solubility of biotinylation reagents that are already soluble to some extent.
== Autobiographical nature == A Scanner Darkly is a fictionalized account of real events, based on Dick's experiences in the 1970s drug culture. Dick said in an interview, "Everything in A Scanner Darkly I actually saw." Between mid-1970 (when his fourth wife Nancy left him) and mid-1972, Dick lived semi-communally with a rotating group of mostly teenage drug users at his home in Marin County, described in a letter as being located at 707 Hacienda Way, Santa Venetia. Dick explained, "[M]y wife Nancy left me in 1970. I got mixed up with a lot of street people, just to have somebody to fill the house. She left me with a four-bedroom, two-bathroom house and nobody living in it but me. So I just filled it with street people and I got mixed up with a lot of people who were into drugs." During this period, the author ceased writing completely and became fully dependent upon amphetamines, which he had been using intermittently for many years. "I did take amphetamines for years in order to be able to—I was able to produce 68 final pages of copy a day," Dick said. The character of Donna was inspired by an older teenager who became associated with Dick sometime in 1970; though they never became lovers, the woman was his principal female companion until early 1972, when Dick left for Canada to deliver a speech to a Vancouver science fiction convention. This speech, "The Android and the Human", served as the basis for many of the recurring themes and motifs in the ensuing novel.
Automated analyzers have to be regularly calibrated. Most manufacturers provide preserved blood with defined parameters and the analyzers are adjusted if the results are outside defined thresholds. To ensure that results continue to be accurate, quality control samples, which are typically provided by the instrument manufacturer, are tested at least once per day. The samples are formulated to provide specific results, and laboratories compare their results against the known values to ensure the instrument is functioning properly. For laboratories without access to commercial quality control material, an Indian regulatory organization recommends running patient samples in duplicate and comparing the results. A moving average measurement, in which the average results for patient samples are measured at set intervals, can be used as an additional quality control technique. Assuming that the characteristics of the patient population remain roughly the same over time, the average should remain constant; large shifts in the average value can indicate instrument problems. The MCHC values are particularly useful in this regard. In addition to analyzing internal quality control samples with known results, laboratories may receive external quality assessment samples from regulatory organizations. While the purpose of internal quality control is to ensure that analyzer results are reproducible within a given laboratory, external quality assessment verifies that results from different laboratories are consistent with each other and with the target values.
Perchloric acid forms perchlorate esters, e.g., methyl perchlorate (CH3−O−Cl(=O)3) Sulfuric acid forms sulfate esters, e.g., dimethyl sulfate ((CH3−O−)2S(=O)2) and methyl bisulfate (CH3−O−S(=O)2−OH) Nitric acid forms nitrate esters, e.g. methyl nitrate (CH3−O−NO2) and nitroglycerin (CH(−O−NO2)(−CH2−O−NO2)2) Phosphoric acid forms phosphate esters, e.g. triphenyl phosphate (O=P(−O−C6H5)3) and methyl dihydrogen phosphate (O=P(−O−CH3)(−OH)2) Pyrophosphoric (diphosphoric) acid forms pyrophosphate esters, e.g. tetraethyl pyrophosphate, ADP, dADP, ADPR, cADPR, CDP, dCDP, GDP, dGDP, UDP, dTDP, MEcPP, HMBPP, DMAPP, IPP, GPP, FPP, GGPP, ThDP, FAD, NAD, NADP. Triphosphoric acid forms triphosphate esters, e.g. ATP, dATP, CTP, dCTP, GTP, dGTP, UTP, dTTP, ITP, XTP, ThTP, AThTP. Tetraphosphoric acid forms tetraphosphate esters, e.g. hexaethyl tetraphosphate, adenosine tetraphosphate (ATPP, Ap4), Ap4A. Carbonic acid forms carbonate esters, e.g. dimethyl carbonate ((CH3−O−)2C=O) and 5-membered cyclic ethylene carbonate ((−CH2−O−)2C=O) (if one classifies carbonic acid as an inorganic compound) Trithiocarbonic acid forms trithiocarbonate esters, e.g. dimethyl trithiocarbonate ((CH3−S−)2C=S) (if one classifies trithiocarbonic acid as an inorganic compound) Chloroformic acid forms chloroformate esters, e.g. methyl chloroformate (Cl−C(=O)−O−CH3) (if one classifies chloroformic acid as an inorganic compound) Boric acid forms borate esters, e.g.
Sources: en.wikipedia.org
Diazepam undergoes oxidative metabolism by demethylation (CYP2C9, 2C19, 2B6, 3A4, and 3A5), hydroxylation (CYP3A4 and 2C19) and glucuronidation in the liver as part of the cytochrome P450 enzyme system. It has several pharmacologically active metabolites. The main active metabolite of diazepam is desmethyldiazepam (also known as nordazepam or nordiazepam). Its other active metabolites include the minor active metabolites temazepam and oxazepam. These metabolites are conjugated with glucuronide and are excreted primarily in the urine. Because of these active metabolites, the serum values of diazepam alone are not useful in predicting the effects of the drug. Diazepam has a biphasic half-life of about one to three days and two to seven days for the active metabolite desmethyldiazepam. Most of the drug is metabolized; little diazepam is excreted unchanged. The elimination half-life of diazepam and also the active metabolite desmethyldiazepam increases significantly in the elderly, which may result in prolonged action, as well as accumulation of the drug during repeated administration.
Peukert argued there was a disconnect between the popular image today of the Nazi era as a time of unparalleled horror vs. the way in which most ordinary Germans remembered it as a time of benign "normality", and that studying Alltagsgeschichte would explore what the Third Reich was actually like in "everyday life". In the early 1980s, Alltagsgeschichte exploded in popularity in West Germany with numerous work groups being set, usually by left-wing groups, to explore the history of their home towns in the Nazi era. The study of Alltagsgeschichte was greatly influenced by the History Workshop movement in Britain set up by the Marxist historian E.P. Thompson and like the British Workshop groups, many involved in the Alltagsgeschichte study groups were not historians with a disproportional number of the volunteers being high-school students. The American historian Mary Nolan wrote with some envy about the way in which thousands of German high school students became involved in the Alltagsgeschichte study groups, observing that it was simply inconceivable that thousands of American high school students would join study groups to research the histories of their home towns in the 1930s-1940s as most Americans have no interest in history. In 1984, Peukert was awarded the annual culture prize given by the city of Essen for his work with a history workshop group in Essen.
Samson admitted that she was not familiar with the topic, but found it to be really interesting. She also explained that Mia has "a bit of tunnel vision" and feels that adopting a child will solve her problems, where Ari is more realistic about their situation. Samson believed Mia was using it as a way to channel her grief. Later scenes see Ari and Mia discussing adoption with John because he adopted his son, and while his experience is different from what Ari and Mia's would be, he gives them hope. The couple soon realise that Ari's criminal record might put a halt to their plans. Samson said "It just makes Mia more determined! Ari is quite worried about it from early on, but nothing is going to stop Mia..." In addition to this, Jasmine Delaney (Sam Frost) offers to sell the gym to Mia, which excites her as she would have something of her own and it will look good on the adoption application. The couple later become engaged, after Ari proposes to Mia. Barrett commented that her character is "ecstatically happy" for her mother and Ari, as she knows how much they love each other. Towards the end of 2021, producers introduced Chloe's biological father Matthew Montgomery (James Sweeny). This also led to further exploration of Mia's backstory, as it emerges that Matthew sexually assaulted her the night Chloe was conceived. A spokesperson for the serial told Sarah Ellis (Inside Soap) that Chloe has always seen Ari as a father figure because he has been in her life since she was young.
(The singer Maurice Gibb is understood to have died from this.) Angiodysplasia of the colon Constipation Diarrhea Hirschsprung's disease (aganglionosis) Intussusception Polyp (medicine) (see also colorectal polyp) Pseudomembranous colitis Toxic megacolon usually a complication of ulcerative colitis
Sources: en.wikipedia.org
Montclair-Boonton Line to Montclair State University station, with connecting service west to Hackettstown. Morris and Essex Lines, consisting of the Morristown Line to Dover via Morristown and the Gladstone Branch to Gladstone. Northeast Corridor Line to Trenton North Jersey Coast Line to Long Branch and Bay Head Raritan Valley Line to Raritan and High Bridge NJT normally uses tracks 1 to 4 exclusively, as these four tracks end at bumper blocks to their east. NJT shares tracks 5 through 12 with Amtrak, and occasionally uses tracks 13 to 16, which are shared with Amtrak and the LIRR.
Aeroponic techniques have proven to be commercially successful for propagation, seed germination, seed potato production, tomato production, leaf crops, and micro-greens. Since inventor Richard Stoner commercialized aeroponic technology in 1983, aeroponics has been implemented as an alternative to water intensive hydroponic systems worldwide. A major limitation of hydroponics is the fact that 1 kilogram (2.2 lb) of water can only hold 8 milligrams (0.12 gr) of air, no matter whether aerators are utilized or not. Another distinct advantage of aeroponics over hydroponics is that any species of plants can be grown in a true aeroponic system because the microenvironment of an aeroponic can be finely controlled. Another limitation of hydroponics is that certain species of plants can only survive for so long in water before they become waterlogged. In contrast, suspended aeroponic plants receive 100% of the available oxygen and carbon dioxide to their roots zone, stems, and leaves, thus accelerating biomass growth and reducing rooting times. NASA research has shown that aeroponically grown plants have an 80% increase in dry weight biomass (essential minerals) compared to hydroponically grown plants. Aeroponics also uses 65% less water than hydroponics. NASA concluded that aeroponically grown plants require ¼ the nutrient input compared to hydroponics. Unlike hydroponically grown plants, aeroponically grown plants will not suffer transplant shock when transplanted to soil, and offers growers the ability to reduce the spread of disease and pathogens.
Discovered in 1913 and classified as a historical monument in 1916, this wall was in the cellar of a house. Some archaeologists of the time thought they had discovered the rampart that Crinas, a wealthy doctor from Marseilles living in Rome, had built at his own expense in the course of the 1st century. This wall is actually older and dates from the 2nd century BC, but nonetheless kept the name. This is the external facing of the rampart, the internal facing having disappeared but being found in the foundations.
Baker's yeast Bioaerosol Ethanol fermentation Evolution of aerobic fermentation Kazachstania yasuniensis – a yeast isolated in 2015 Mycosis (fungal infection in animals) Start point (yeast) WHI3 Yeast plasmids Zymology
Juan Vucetich, an Argentine chief police officer, created the first method of recording the fingerprints of individuals on file. In 1892, after studying Galton's pattern types, Vucetich set up the world's first fingerprint bureau. In that same year, Francisca Rojas of Necochea was found in a house with neck injuries whilst her two sons were found dead with their throats cut. Rojas accused a neighbour, but despite brutal interrogation, this neighbour would not confess to the crimes. Inspector Alvarez, a colleague of Vucetich, went to the scene and found a bloody thumb mark on a door. When it was compared with Rojas' prints, it was found to be identical with her right thumb. She then confessed to the murder of her sons. A Fingerprint Bureau was established in Calcutta (Kolkata), India, in 1897, after the Council of the Governor General approved a committee report that fingerprints should be used for the classification of criminal records. Working in the Calcutta Anthropometric Bureau, before it became the Fingerprint Bureau, were Azizul Haque and Hem Chandra Bose. Haque and Bose were Indian fingerprint experts who have been credited with the primary development of a fingerprint classification system eventually named after their supervisor, Sir Edward Richard Henry. The Henry Classification System, co-devised by Haque and Bose, was accepted in England and Wales when the first United Kingdom Fingerprint Bureau was founded in Scotland Yard, the Metropolitan Police headquarters, London, in 1901. Sir Edward Richard Henry subsequently achieved improvements in dactyloscopy.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.